Evommune Company Overview, Contact Details & Competitors

Q: What is Evommune's official website and social media links?

Evommune's official website is evommune.com. Evommune has social profiles on LinkedIn.

Q: How many employees does Evommune have currently?

Evommune has approximately 57 employees.

Q: What technology does Evommune use?

Evommune's tech stack includes Adobe Fonts, ManageEngine, SAS, oEmbed, Cloudflare.

Q: What is Evommune's NAICS code?

Evommune's NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Insights

Gathering insights about Evommune…

Similar companies to Evommune

Evommune Tech Stack

Evommune uses 8 technology products and services including SAS, Amazon CloudFront, RSS, and more. Explore Evommune's tech stack below.

SAS
Business Intelligence
Amazon CloudFront
Content Delivery Network
RSS
Content Management System
JSON-LD
Javascript Frameworks
AOS
Javascript Libraries
macOS
Operating Systems & Computing Languages
Apache
Web Servers
easy pie chart
Web Tools And Plugins

Media & News

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. “We continue to make meaningful progress across our broad chronic inflammation targeted pipeline and remain on track to deliver top-line Phase 2b data for.
May 07, 2026 | www.businesswire.com
Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript
Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript
Apr 14, 2026 | seekingalpha.com
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced it will host a webinar highlighting the migraine treatment landscape and the role of MRGPRX2 inhibition on this debilitating condition on Monday, April 13, 2026, at 11:00 a.m. PT (2:00 p.m. ET). The event will include presentations from members of.
Apr 06, 2026 | www.businesswire.com
Capricorn Fund Managers Ltd Acquires Shares of 60,000 Evommune, Inc. $EVMN
Capricorn Fund Managers Ltd acquired a new stake in Evommune, Inc. (NYSE: EVMN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 60,000 shares of the company's stock, valued at approximately $1,027,000. Capricorn Fund Managers Ltd owned about 0.19% of Evommune as
Apr 06, 2026 | www.defenseworld.net
Evommune, Inc. (NYSE:EVMN) Receives Average Rating of “Moderate Buy” from Analysts
Shares of Evommune, Inc. (NYSE: EVMN - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eleven research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have issued a buy recommendation and
Mar 11, 2026 | www.defenseworld.net
1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade
Clinical-stage biotech Evommune is seen as a potential buyout candidate. Its shares are up more than 55% so far this year.
Mar 10, 2026 | www.fool.com
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. “The positive top-line Phase 2a data for EVO301 marks an important milestone for Evommune and further validates IL-18 inhibition as a co.
Mar 05, 2026 | www.businesswire.com

Evommune's Email Address Formats

Evommune uses at least 1 format(s):

Evommune Email Formats	Example	Percentage
First.Last@evommune.com	John.Doe@evommune.com	100%

Frequently Asked Questions

Where is Evommune's headquarters located?

Evommune's main headquarters is located at Palo Alto, California United States. The company has employees across 4 continents, including North AmericaAsiaEurope.

What is Evommune's stock symbol?

Evommune is a publicly traded company; the company's stock symbol is EVMN.

What is Evommune's official website and social media links?

Evommune's official website is evommune.com and has social profiles on LinkedIn Crunchbase.

What is Evommune's SIC code NAICS code?

Evommune's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Evommune have currently?

As of May 2026, Evommune has approximately 57 employees across 4 continents, including North AmericaAsiaEurope. Key team members include Chief Business And Legal Officer; Corporate Secretary And Chief Compliance Officer: G. M.Chief Financial Officer: K. C.Chief Scientific Officer: J. P.. Explore Evommune's employee directory with LeadIQ.

What industry does Evommune belong to?

Evommune operates in the Biotechnology Research industry.

What technology does Evommune use?

Evommune's tech stack includes SASAmazon CloudFrontRSSJSON-LDAOSmacOSApacheeasy pie chart.

What is Evommune's email format?

Evommune's email format typically follows the pattern of First.Last@evommune.com. Find more Evommune email formats with LeadIQ.

When was Evommune founded?

Evommune was founded in 2020.

Insights

Similar companies to Evommune

Ro

Cove

Capsule

FOLX Health

Forward

Maven Clinic

Thirty Madison

Evommune Tech Stack

Media & News

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Capricorn Fund Managers Ltd Acquires Shares of 60,000 Evommune, Inc. $EVMN

Evommune, Inc. (NYSE:EVMN) Receives Average Rating of “Moderate Buy” from Analysts

1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Evommune's Email Address Formats

Frequently Asked Questions

Where is Evommune's headquarters located?

What is Evommune's stock symbol?

What is Evommune's official website and social media links?

What is Evommune's SIC code NAICS code?

How many employees does Evommune have currently?

What industry does Evommune belong to?

What technology does Evommune use?

What is Evommune's email format?

When was Evommune founded?

Evommune

Company Overview

Media & News

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?